Development and validation of a novel bioassay to determine glucocorticoid sensitivity

Emily L Williams, Madeleine L Stimpson, Peter L Collins, Doyo G. Enki, Ashish Sinha, Richard W Lee, Ashwin D Dhanda

Research output: Contribution to journalArticle (Academic Journal)peer-review

2 Citations (Scopus)
190 Downloads (Pure)

Abstract

BACKGROUND: Glucocorticoids (GCs) remain the first line treatment for almost all non-infectious inflammatory diseases, ranging from acute asthma to rheumatoid arthritis. However, across all conditions, patients have a variable response to GCs with approximately 30% being non-responders. This group of GC resistant patients is typically exposed to high-dose GCs and their side-effects before more appropriate immunotherapy is instituted. Hence, there is a pressing clinical need for a predictive biomarker of GC responsiveness. The availability of such a tool would also enable patient stratification for the conduct of smart clinical trials in GC resistance. Lymphocyte GC sensitivity has been shown to be closely associated with clinical GC sensitivity in a number of inflammatory diseases. However, the method for determining in vitro GC response is not standardized and requires the use of specialist equipment, including a radioisotope to quantify cellular proliferation, making it challenging to translate into clinical practice.

RESULTS: Here we describe the optimization and validation of a novel non-radioactive in vitro bioassay based on measuring cellular proliferation by incorporation of bromodeoxyuridine (BrdU), termed the BrdU incorporation in lymphocyte steroid sensitivity assay (BLISS). In comparison to the current gold standard lymphocyte GC sensitivity assay in 101 healthy control samples, BLISS has an area under receiver operating characteristic of 0.82 and a sensitivity of 83% for correctly identifying GC resistant subjects.

CONCLUSIONS: The performance of the novel BLISS bioassay makes it a strong candidate biomarker for clinical application. It now requires validation in a prospective patient cohort.

Original languageEnglish
Pages (from-to)26
Number of pages7
JournalBiomarker Research
Volume4
Issue number26
DOIs
Publication statusPublished - 15 Dec 2016

Fingerprint Dive into the research topics of 'Development and validation of a novel bioassay to determine glucocorticoid sensitivity'. Together they form a unique fingerprint.

Cite this